Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation

Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To An Alprazolam Sublingual Tablet

This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing sublingual formulation.

Inclusion Criteria:

• healthy male or female subjects
• BMI 18 to 26.9
• must give informed consent

Exclusion Criteria:

• clinically significant disease
• narrow angle glaucoma
• positive drug screen